Hit enter to search or ESC to close

Category: Investor Announcement

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson’s Disease and Movement Disorders (MDS 2020) and the American Neurological Association’s 2020 Annual Meeting (ANA 2020). ...

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company’s lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. The company recently ...

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting. Chief Medical Officer & Senior VP Clinical Development, Dr David Stamler had been invited to make an oral presentation at the Parkinson’s ...

Alterity receives a $4.8 million R&D Tax Incentive Refund

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme. The refund relates to the cost of eligible research and development activities conducted during the 2019 financial year.  These funds will be used to ...

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA).  Orphan Drug designation by the EC entitles Alterity to ten years of market exclusivity in the European Union for the ...

Alterity AGM Investor Conference Call

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference. The AGM is scheduled for 9:30 AM (Australian Eastern Daylight Time) Tuesday, November 26th, 2019 at the Adina Apartment Hotel, 189 Queen Street, Melbourne. Registration is from 9:15 AM. To ...

Alterity’s lead drug candidate receives positive opinion from European medical agency

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on recommending the designation of its lead molecule PBT434 for the treatment of Multiple System Atrophy (MSA) as an orphan medicinal product to the European Commission (EC). Following ...